The estimated Net Worth of Venture Capital Iii, L.P.Ve... is at least $29.5 million dollars as of 18 February 2014. Venture Ve owns over 307,692 units of Flexion Therapeutics Inc stock worth over $29,470,556 and over the last 11 years Venture sold FLXN stock worth over $0.
Venture has made over 1 trades of the Flexion Therapeutics Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently Venture bought 307,692 units of FLXN stock worth $3,999,996 on 18 February 2014.
The largest trade Venture's ever made was buying 307,692 units of Flexion Therapeutics Inc stock on 18 February 2014 worth over $3,999,996. On average, Venture trades about 307,692 units every 0 days since 2014. As of 18 February 2014 Venture still owns at least 3,206,807 units of Flexion Therapeutics Inc stock.
You can see the complete history of Venture Ve stock trades at the bottom of the page.
Over the last 11 years, insiders at Flexion Therapeutics Inc have traded over $7,066,621 worth of Flexion Therapeutics Inc stock and bought 7,091,809 units worth $98,920,816 . The most active insiders traders include Holdings A/S Novo, Bradley J Ph D Bolzon et Samuel D Colella. On average, Flexion Therapeutics Inc executives and independent directors trade stock every 24 days with the average trade being worth of $609,564. The most recent stock trade was executed by Christina Willwerth on 19 July 2021, trading 3,945 units of FLXN stock currently worth $25,445.
Flexion Therapeutics is a biopharmaceutical company focused on the development and commercialization of novel, local therapies for the treatment of people with musculoskeletal conditions, beginning with osteoarthritis, the most common form of arthritis. The Company's core values are focus, ingenuity, tenacity, transparency and fun.
Flexion Therapeutics Inc executives and other stock owners filed with the SEC include: